Bajaj Healthcare Ltd announces successful completion of USFDA pre approval inspection at API facility

Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, announces successfully competition of first ever pre approval inspection of United State Food and Drug Administration (USFDA) of its API facility located at Vadodara, Gujarat.

The US Food and drug administration (USFDA) has conducted it's pre approval inspection of its API facility located at Vadodara, Gujarat from November 14, 2022 to November 17,2022. The pre-approval inspection of United State Food and Drug Administration (USFDA) has completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited.

Commenting on the above business update, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "I am happy to announce that we successfully completed first ever pre approval USFDA inspection with ZERO 483 observation at our API Manufacturing facilities located at Vadodara, Gujarat. We are committed to strict adherence to all applicable guidelines and regulations and maintaining the highest quality standards in delivering quality services and timely delivery to our clients."

Source : Equity Bulls

Keywords

BajajHealthcare PreApprovalInspection USFDA Vadodara APIFacility Gujarat